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Abstract. 
 
A 104-kD protein was coimmunoprecipitated 
with the estrogen receptor from the flowtrough of a 
phosphocellulose chromatography of MCF-7 cell nuclear 
extract. mAbs to this protein identified several cDNA 
clones coding for the human 104-kD major vault protein. 
Vaults are large ribonucleoprotein particles of unknown 
function present in all eukaryotic cells. They have a com-
plex morphology, including several small molecules of 
RNA, but a single protein species, the major vault pro-
 
tein, accounts for 
 
.
 
70% of their mass. Their shape is 
reminiscent of the nucleopore central plug, but no pro-
teins of known function have been described to interact 
with them. Western blot analysis of vaults purified on su-
crose gradient showed the presence of estrogen receptor 
co-migrating with the vault peak. The AER317 antibody 
to estrogen receptor coimmunoprecipitated the major 
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vault protein and the vault RNA also in the 20,000 
 
g
 
 su-
pernatant fraction. Reconstitution experiments of estro-
gen receptor fragments with the major vault protein 
mapped the site of the interaction between amino acids 
241 and 280 of human estrogen receptor, where the nu-
clear localization signal sequences are located. Estradiol 
treatment of cells increased the amount of major vault 
protein present in the nuclear extract and coimmunopre-
cipitated with estrogen receptor, whereas the anti-estro-
gen ICI182,780 had no effect. The hormone-dependent 
interaction of vaults with estrogen receptor was repro-
ducible in vitro
 
 
 
and was prevented by sodium molyb-
date. Antibodies to progesterone and glucocorticoid re-
ceptors were able to coimmunoprecipitate the major 
vault protein. The association of nuclear receptors with 
vaults could be related to their intracellular traffic.
 
V
 
ault
 
 ribonucleoprotein particles are present in all
eukaryotic cells and their structure and protein
composition are highly conserved (Kedersha et al.,
 
1990). They have a characteristic ovoid shape made by two
halves connected on the equatorial plane. Each half con-
tains eight petals and a central ring (Kedersha et al., 1990).
The vault particle has a mass of 
 
z
 
13 MD, corresponding
to a sedimentation coefficient of 150 S. One single protein
species constitutes 
 
.
 
70% of the particle mass and a small
molecule of RNA is part of this complex structure. It has
been calculated that each petal contains six major vault
protein copies and one vRNA molecule, for a total of 96
and 16 molecules, respectively, in each vault particle (Ked-
ersha et al., 1991). Vaults were originally identified in the
postmicrosomal supernatant of cell extracts, but it has also
been reported that they were present in isolated nuclei
(Chugani et al., 1993). Immunocytochemical localization
showed perinuclear staining of cultured fibroblasts. Be-
cause of their size, shape, and protein and RNA compo-
sition, these particles are different from other ribonu-
cleoproteins. The conservation of protein sequence and
particle shape between organisms from lower eukaryotes
to man is indicative of a central role in cell function. Dis-
ruption of major vault proteins in 
 
Dictyostelium discoi-
deum
 
 results in a phenotype incapable of growing under
nutritional stress (Vasu and Rome, 1995). However, the
vault function still remains an enigma. Structural similari-
ties and immunocytochemical data suggest that vaults may
constitute the central plug of the nucleopore structure, in-
volved in the protein and/or RNA transport between cyto-
plasm and nucleus (Chugani et al., 1993). More recently it
has been demonstrated that the lung resistance–related
 
protein (LRP)
 
1
 
 is the human major vault protein (Scheffer
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et al., 1995). LRP is a protein overexpressed in many neo-
plastic tissue and cell lines (Izquierdo et al., 1996). Its ex-
pression has been related to a phenotype resistant to che-
motherapy (Izquierdo et al., 1995) and it has a high
predictive value for a poor response to chemotherapy
(List et al., 1996). However, neither the function of this
protein in normal cell have been elucidated nor its role in
drug resistance mechanism. Several other minor polypep-
tides are present in the assembled vaults (Kedersha and
Rome, 1986), but none of them have been characterized so
far. No other proteins with a defined function and interact-
ing with vault particles have been described to date. Data
reported in this article indicate that the estrogen receptor
(and other steroid receptors) interact with the major vault
protein and might, therefore, represent a breakthrough in
describing the function of vaults.
Estrogen receptor is the protein responsible for the bio-
logical action of estradiol. Binding to specific sequences
present in the regulatory region of controlled genes (the
hormone responsive element) is a mandatory step in the
hormonal mechanism of action (Beato, 1989). Occupation
of the hormone binding site modulates the accessibility of
the receptor DNA-binding domain to DNA and the tran-
scriptional activation function (Tora et al., 1989
 
b
 
; Beato et
al., 1995). Protein–protein interaction with components of
the transcription initiation complex and/or with adapters
bridging receptor and transcription initiation complex me-
diates transcriptional activation (Ing et al., 1992; Cavaillès
et al., 1994, 1995; Halachmi et al., 1994; Jacq et al., 1994;
Le Douarin et al., 1995; Oñate et al., 1995; Voegel et al.,
1996; vom Baur et al., 1996). Other steps involved in the
hormone mechanism of action, such as DNA binding
(Landel et al., 1994), availability of the C-domain for
DNA binding and intracellular partitioning of the receptor
may be influenced by protein–protein interaction. Fur-
thermore access to transcriptionally repressed chromatin
is probably mediated by the histone acetyltransferase ac-
tivity of steroid receptor coactivator SRC-1, a protein in-
teracting with steroid receptor in a hormone-dependent
manner (Spencer et al., 1997). The first described protein–
protein interaction for estrogen receptor has been with a
90-kD heat shock protein (
 
hsp
 
90), forming a quaternary
structure known as “native receptor” (Ziemiecki et al.,
1986; Redeuihl et al., 1987). The 
 
hsp
 
90 does not interfere
with the hormone binding, but it shields the DNA-binding
domain, preventing the interaction with the hormone-
responsive element (Binart et al., 1989). Estradiol binding
induces a conformational modification in the receptor
molecule, releasing the 
 
hsp
 
90 from the hormone binding
subunit. 
 
hsp
 
90 is a protein present in the cell cytoplasm,
but estrogen receptor has been visualized by immunocy-
tochemistry both in the cytoplasm and in the nucleus
(King and Greene, 1984; Marchetti et al., 1987). In the
hinge region (D domain), three lysine-/arginine-rich mo-
tifs have been identified, representing constitutive nuclear
localization signals (Picard et al., 1990). A fourth, estro-
gen-regulated nuclear localization signal has been identi-
fied in the hormone binding domain (Ylikomi et al., 1992).
Similar nuclear localization signals have also been re-
ported for other steroid receptors. Nuclear localization
signals are responsible for nuclear targeting of protein, a
process that includes binding to nuclear pore components
 
and energy-dependent transport (Pantè and Aebi, 1996;
Nigg, 1997). No interaction of estrogen receptor with
known components of the nucleopore or with shuttling
carriers has been described so far.
 
Materials and Methods
 
Materials
 
[
 
3
 
H]Estradiol (84–111 Ci/mmol), [
 
32
 
P]
 
a
 
-ATP (3,000 Ci/mmol), peroxi-
dase-conjugated anti–mouse immunoglobulins, and chemiluminescent
substrate (ECL) were from Amersham (Aylersbury, Bucks, United King-
dom). Freund’s adjuvants, anti–mouse immunoglobulin coupled to aga-
rose, BSA, and rabbit polyclonal antibodies to estrogen receptor (amino
acids [aa] 154–171) were from Sigma Chemical Co. (St. Louis, MO). Pro-
tein A– and protein G–Sepharose FF-4B, CNBr-activated Sepharose,
DEAE Fast Flow column, and pGEX-2TK plasmid were from Pharmacia
Biotech Sevrage (Uppsala, Sweden). DTT, tris-HCl, Hepes, acrylamide,
bisacrylamide, and 
 
b
 
-lactoglobulin were from Serva (Heidelberg, Ger-
many). Tissue culture media, antibiotics, and FCS (Myoclone 
 
1
 
) were
from Gibco Laboratories (Grand Island, NY). BM-Condimed
 
®
 
 H1,
tRNA, and protease inhibitors were from Boehringer Mannheim GmbH
(Mannheim, Germany). HeLa cell expression library was from CLON-
TECH (Palo Alto, CA). Anti–mouse IgG isotype were from Caltag Labs
(South San Francisco, CA). Restriction enzymes, T7 DNA polymerase,
T4 polynucleotide kinase, and other molecular biology reagents were
from Promega Corp. (Madison, WI). Dynabeads S-280 were from Dynal
AS (Oslo, Norway). Blocking reagent was from Bio-Rad Laboratories
(Hercules, CA). Rabbit polyclonal antibodies to progesterone receptor
(aa 545–564), to glucocorticoid receptor (aa 5–20), to Nurr77 (aa 4–23), to
TFIIB (aa 299–316), and to steroid receptor cofactor-1 (SRC-1) were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Mouse mAbs to proges-
terone receptor C-262 was from StressGen Biotechnology Corp. (Victoria
BC, Canada). All other reagents were of analytical grade.
 
Buffers and Solutions
 
Buffer A: 10 mM Hepes, pH 7.9, 10 mM KCl, 0.5 mM DTT, 1.5 mM
MgCl
 
2
 
; buffer C: 20 mM Hepes, pH 7.9, 450 mM NaCl, 0.2 mM DTT, 1.5
mM MgCl
 
2
 
, 0.5 mM EDTA, 0.5 mM PMSF, 25% (vol/vol) glycerol; buffer
D: 20 mM Hepes, pH 7.8, 100 mM KCl, 0.5 mM DTT, 0.1 mM EDTA,
15% (vol/vol) glycerol, 10% (wt/vol) sucrose, 0.5 mM PMSF; buffer PC:
20 mM Hepes, pH 7.9, 0.01 mM ZnCl
 
2
 
, 1.5 mM MgCl
 
2
 
, 1 mM DTT, 10%
(vol/vol) glycerol; buffer HMEG: 20 mM Hepes, pH 7.9, 2 mM MgCl
 
2
 
, 0.1
mM EDTA, 100 mM KCl, 1 mM DTT, 15% (vol/vol) glycerol, 10% (wt/
vol) sucrose, 0.1% NP-40; buffer H1: 20 mM Hepes, pH 7.9, 2 mM MgCl
 
2
 
,
0.1 mM EDTA, 100 mM KCl, 1 mM DTT, 10% (vol/vol) glycerol, 0.1%
NP-40; buffer G0: 20 mM Hepes, pH 7.9, 0.1 mM EDTA, 0.1 M potassium
glutamate, 1 mM DTT, 10% (vol/vol) glycerol; buffer G1: buffer G0 con-
taining 1 M guanidium chloride; D’PBS: Dulbecco’s PBS without Ca
 
2
 
1
 
and Mg
 
2
 
1
 
; PBSL: 3 g/liter Na
 
2
 
HPO
 
4
 
, 0.3 g/liter NaH
 
2
 
PO
 
4
 
, 12 g/liter NaCl,
0.05% NP-40, 0.05% Tween 20; WB buffer: PBSL, containing 150 mM
NaCl; HAT: 0.1 mM hypoxantine, 0.4 
 
m
 
M aminopterine, 16 
 
m
 
M thymi-
dine; and SSC buffer: 15 mM sodium citrate, pH 7.0, 150 mM NaCl. All
buffers were filtered through 0.45-
 
m
 
m pore Millipore filters (Bedford, MA).
 
Preparation of Nuclear Extract and
20,000 g Supernatant
 
MCF-7 cells were grown in 140-mm-diam Petri dishes or in 175-cm
 
2
 
 flasks
in RPMI 1640 Dulbecco’s essential medium containing 5% horse serum
(heat inactivated), 5% fetal calf serum (heat inactivated), 7 ng/ml (2 
 
3
 
10
 
2
 
4
 
 USP units/ml) bovine insulin, and 1 nM cortisol. Estradiol depriva-
tion was obtained by growing the cells for a week in medium deprived of
phenol red and added with charcoal-treated sera. Charcoal treatment was
performed by incubation of sera with 0.25% charcoal for 30 min at 56
 
8
 
C
followed by 30 min at 37
 
8
 
C. The procedure was performed twice and the
charcoal separated by centrifugation and filtration. Subconfluent cells
were harvested and processed as described to obtain the nuclear extract
(Dingam et al., 1983). The sample was dialyzed versus buffer D added
with 10% (wt/vol) sucrose and 15% (vol/vol) glycerol, and then clarified
at 14,000 
 
g
 
 for 15 min. Protein concentration was usually between 8 and 9 
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mg/ml. The extract was stored at 
 
2
 
70
 
8
 
C up to 4 wk. The 20,000 
 
g
 
 superna-
tant was obtained by centrifugation at 20,000 
 
g
 
 of the homogenate after
the removal of nuclei
 
.
 
Nuclear Extract Fractionation
 
Phosphocellulose chromatography of cell extract was performed after a
described procedure (Reinberg and Roeder, 1987) and its modifications
(Tanese et al., 1991; Pugh and Tijan, 1991). The sample (
 
z
 
200 mg of pro-
tein extracted from 2 
 
3 
 
25 ml of packed MCF-7 cell) was diluted with an
equal volume of PC buffer containing 0.1 M KCl and applied to a 20-ml
phosphocellulose column equilibrated in the same buffer. The flowthrough
protein peak was collected and the column eluted three times with 60 ml
of PC buffer containing 0.3, 0.5, or 0.75 M KCl. Washes (40 ml) were in-
serted between elutions and discarded. The collected peak fractions were
dialyzed with HMEG buffer, containing 0.1 M KCl and 0.05% NP-40. Pro-
tein recovery was 
 
.
 
85%, distributed as follows: 40–45% in the flowthrough
fraction, 15–28% in the 0.3 M KCl, 11–15% in the 0.5 M KCl, 8–12% in
the 0.75 M KCl. The samples were stored frozen in aliquots at 
 
2
 
70
 
8
 
C for
up to 4 wk.
 
Preparation of Vault-enriched Fractions
 
Cells were harvested, sequentially washed in 50 vol of Dulbecco’s PBS
and 5 vol of buffer A, resuspended in 2 vol of water, and then homoge-
nized using four strokes of a Dounce homogenizer. The homogenate was
added with 1/10 of volume of 200 mM Hepes, pH 7.9, 110 mM potassium
acetate, 50 mM sodium acetate, 20 mM MgCl
 
2
 
, 20 mM DTT, and centri-
fuged at 2,000 
 
g
 
 for 5 min at 4
 
8
 
C. The supernatant, referred to as postnu-
clear supernatant, was subsequently centrifuged at 41,000 
 
g
 
 for 2 h at 4
 
8
 
C.
The pellet, resuspended with buffer H1 containing 20% glycerol, was cen-
trifuged at 20,000 
 
g
 
 for 5 min at 4
 
8
 
C, and the supernatant referred to as
vault-enriched fraction.
 
Preparation of mAbs
 
Production of mAbs AER314 and AER317 to calf uterus estrogen recep-
tor has been previously described (Abbondanza et al., 1993). The mAb
1603 to the human estrogen receptor synthetic fragment was prepared us-
ing the protein purified from
 
 Escherichia coli
 
 cells transfected with
pGEX/hER281-595. The recombinant protein was purified using a two-
dimensional 16-BAC/SDS-PAGE system as described (Macfarlane, 1989),
and then electroeluted. Antibodies production was performed as described
elsewhere (Abbondanza et al., 1993). To prepare antibodies to the 104-kD
protein, 
 
z
 
5 
 
m
 
g of protein, eluted from AER314 or AER317 immunopre-
cipitates of phosphocellulose fractionation of 1 g of nuclear extract pro-
teins, were precipitated with TCA overnight, and resuspended with 0.2 ml
of 10 mM NaOH, 0.1% SDS buffer, pH 7.5, with 0.11 vol of 10
 
3 
 
PBS.
Four Balb-C mice were immunized with that amount of protein, according
to the protocol described (Abbondanza et al., 1993). Spleen cells (7.5 
 
3
 
10
 
7
 
) were fused with an equal number of Sp0Ag-14 myeloma cells in the
presence of 50% polyethylenglycol 1500, and then seeded in four 96-well
microtiter plates in DME/RPMI 1640 medium (1:1), containing 15% Myo-
clone plus, 10% BM condimed H1 and HAT. After 14 d, supernatants
were screened by Western blot analysis of nuclear extract proteins, using a
Multiscreen device (Bio-Rad Laboratories). Wells whose supernatant
showed a positive signal for a 104-kD band were selected and the cells
cloned by limited dilution in the same medium without HAT. Selected
positive clones (series 10
 
nn
 
) were expanded and supernatants collected.
Supernatants were added with 50 mM Tris-HCl, pH 7.5, and 0.05% so-
dium azide, and then stored at 4
 
8
 
C up to 1 yr.
 
Immunoprecipitation
 
The samples (nuclear extract, phosphocellulose column fractions, or
20,000 
 
g
 
 supernatant) were diluted with an equal amount of PC buffer
containing 0.1 M KCl and incubated overnight with the mAb (2–5 
 
m
 
g/10
mg of protein) in the presence of the capturing resin. Antibody–antigen
complexes were captured either by appropriate preabsorbed sheep anti–
mouse IgG isotype coupled to protein G–Sepharose (25 
 
m
 
g/50 
 
m
 
l) for anti-
gen preparation or by anti–mouse IgG coupled to CNBr-activated
Sepharose (50 
 
m
 
l) for analytical purposes. At the end of incubation, resins
were sequentially washed with 30 vol of buffer H1 (three times for 10
min), 10 vol of buffer G0 (2 min), 10 vol of buffer G1, containing 0.2 M
guanidium chloride (2 min). Proteins were eluted with 4 vol of buffer G1,
containing 15 
 
m
 
g/ml of 
 
b
 
-lactoglobulin, clarified at 3,000 
 
g
 
 for 1 min and
precipitated with a final concentration of 10% TCA. Precipitated proteins
were washed twice with diethyl ether-ethanol (1:1), air dried, and then re-
suspended for immunization or in sample buffer for SDS-PAGE analysis.
 
Sucrose Gradients
 
5- or 40-ml 30–60% sucrose gradients were prepared in HEMG buffer
containing 0.1 M KCl. The applied samples were not 
 
.
 
1/15 of the gradient
volume. The 5-ml gradients were centrifuged in a Beckman Vti65 rotor at
50,000 rpm up to 2.8 
 
3 
 
10
 
11
 
 
 
v
 
2
 
t; 40-ml gradients were centrifuged in a
Beckman Vti55 rotor at 50,000 rpm up to 7.8 
 
3 
 
10
 
11
 
 
 
v
 
2
 
t. At the end of the
run, gradients were collected in 20 fractions.
 
Preparation of Synthetic Estrogen Receptor Fragments
 
All the procedures, not described in details, were performed according to
standardized protocols (Ausubel et al., 1996). Fusion protein of estrogen
receptor fragments and glutathione-S-transferase (GST) were obtained by
subcloning the human estrogen receptor cDNA in the EcoRI site of com-
mercial pGEX-2TK plasmid. With such insertion, the human estrogen re-
ceptor cDNA sequence was off the GST open reading frame. To obtain
the fragments of estrogen receptor starting from aa 65, the plasmid was
further digested with BamHI and NotI, and then the ends were filled and
ligated. This plasmid was further digested (
 
a
 
) with StuI and ligated to ob-
tain the fragment from aa 65 to 203 (pGEX/hER65–203); (
 
b
 
) with Hin-
dIII, filled, and then ligated to obtain the fragment from aa 65 to 339
(pGEX/hER65–339); (
 
c
 
) with BglII, filled, and then ligated to obtain the
fragment from aa 65 to 423 (pGEX/hER65–423); (
 
d
 
) with AvaI and
NgoMI, filled, and then ligated to obtain the fragment from aa 241 to 595
(pGEX/hER241–595). Another fusion protein, containing the human es-
trogen receptor fragment from aa 281 to 595 (pGEX/hER281–595) was
obtained by subcloning the filled H14 cDNA BamHI fragment in the
filled EcoRI site of pGEX-2TK plasmid. With such insertion, the human
estrogen receptor cDNA sequence resulted in frame with the GST open
reading frame. A 795-bp fragment was excised from this plasmid by diges-
tion with HindIII and AatII and replaced with a similar fragment excised
from pGEX/hER65–595, to obtain a fragment with a glycine at position
400 (Tora et al., 1989
 
a
 
). The fragment was dephosphorylated and purified
by electrophoresis before ligation. The plasmids were transfected in the
JM109 
 
E. coli
 
 strain. Bacterial growth and fusion protein purification were
performed according to supplier’s instructions with the following modifi-
cation: after cell lysis by addition of lysozyme and three cycles of freezing-
thawing, the lysate was added with 0.5% NP-40, 0.5 mg/ml bacitracin, 10
 
m
 
g/ml leupeptin, and 1 mM PMSF, and then centrifuged at 18,000 rpm for
15 min. Synthetic proteins were tested by SDS-PAGE followed by West-
ern blot analysis with mAbs to estrogen receptor of the AER3
 
nn
 
 series
and for estradiol binding activity (Moncharmont et al., 1991).
 
RNA Analysis
 
RNA coimmunoprecipitated from nuclear extract or 20,000 
 
g
 
 supernatant
was extracted with an equal volume of non-buffered phenol/chloroform
(1:1) and ethanol precipitated at 
 
2
 
20
 
8
 
C for 1 h in the presence of 0.3 
 
m
 
l/
sample of SeeDNA (Amersham). The pellet was washed twice with 75%
ethanol, dried, resuspended in denaturing solution, denatured, and then
electrophoresed on a 2.2% agarose gel as described (Ausubel et al., 1996).
Nucleic acid was transferred onto a nylon membrane (Hybond-N; Amer-
sham) by capillarity, and the membrane further processed according to
manufacturer’s instructions. The membrane was hybridized with the radio-
labeled probe at 42
 
8
 
C overnight, and washed with 2
 
3 
 
SSC containing
0.1% SDS at room temperature (Ausubel et al., 1996). Human vault RNA
(vRNA) probe was prepared by reverse transcription and PCR amplifica-
tion of total MCF-7 RNA. Total RNA extraction (guanidine isothiocyan-
ate method), reverse transcription, and PCR amplification were per-
formed according to published protocols (Ausubel et al., 1996). The
primers 5
 
9
 
-GGYCAGCWWYAGCTCAGCGGTTACTTC-3
 
9
 
 and 5
 
9
 
-GYC-
AGRKRGCGCCCGCGGGTYTCGAACC-3
 
9
 
 used for the amplification
were derived from rat and bullfrog vRNA sequences (Kickhoefer et al.,
1993). The resulting product, purified by agarose electrophoresis, was ra-
diolabeled by Multiprime DNA labeling systems (Amersham) and used as
probe for the Northern blot analysis. To confirm that the amplified prod-
uct was the human vRNA, the fragment was subcloned in pBluescriptSK.
12 clones were analyzed by insert sequencing (Sanger et al., 1977). Two
different fragments (hvRNA82 and hvRNA92) were cloned of 82 and 92
bp, respectively, sharing a high percent of identity with rat and bullfrog 
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vRNAs. These sequence data are available from GenBank/EMBL/DDBJ
under accession No. AF058296 and AF058297, respectively.
 
Estrogen Receptor Affinity Chromatography
 
Estrogen receptor fragments–GST fusion proteins were coupled to glu-
tathione–Sepharose according to manufacturer’s instructions. Aliquots
(2 mg) of the nuclear extracts were added with 0.5% NP-40, diluted with
an equal volume of buffer H1 and incubated overnight at 4
 
8
 
C with 25 
 
m
 
l of
resin. The resins were then washed, as indicated above, and eluted with
sample buffer (Laemmli, 1970). The samples were subjected to SDS-
PAGE followed by Western blot analysis with the mAb 1032 to the major
vault protein.
 
Screening of a HeLa Cell cDNA Library
 
A commercial 
 
l
 
gt-11 expression library from HeLa S3 cell line was plated
and screened according to manufacturer’s directions. Two mAbs to the
104-kD protein (1032 and 1014) were used for the screening. The antibody
presence on the nitrocellulose replicas was revealed by peroxidase-cou-
pled anti–mouse IgG using chemiluminescent substrate (ECL; Amer-
sham) according to manufacturer’s instructions. The inserts of two posi-
tive clones were amplified using specific 
 
l
 
gt-11 primers and subcloned in
pGEM. Sequence analysis was performed on both strands of the inserts
(700 and 500 bp, respectively), using T7 DNA polymerase (Sanger et al.,
1977).
 
Electrophoresis and Western Blot Analysis
 
SDS-PAGE and Coomassie blue staining of proteins were performed as
described elsewhere (Laemmli, 1970). For Western blot analysis proteins
were electrophoretically transferred to a 0.45-
 
m
 
m nitrocellulose sheet in
WB buffer (Towbin et al., 1979). Nitrocellulose reactive groups were then
blocked for 1 h with a 5% solution of blocking reagent in WB buffer. Pri-
mary antibody incubation was performed overnight at 4
 
8
 
C or for 3 h at
room temperature using a 1:10 or 1:20 dilution of hybridoma cell superna-
tant in WB buffer containing 2% solution of blocking reagent (0.25 ml/
cm
 
2
 
). At the end of incubation, blots were washed once for 15 min and
three times for 5 min with WB buffer. Antibody reaction was revealed by
incubation for 1 h at room temperature with enzyme-coupled anti–mouse
IgG (1:10,000 dilution for HRP-coupled antibodies; Amersham or 1:30,000
dilution for alkaline phosphatase–coupled antibodies; Sigma Chemical Co.)
in WB buffer containing 0.5% solution of blocking reagent (0.25 ml/cm
 
2
 
),
followed by a washing cycle (as above) and using chemiluminescent sub-
strate (ECL; Amersham) (Immunolite; Bio-Rad Laboratories) according
to manufacturer’s instructions.
 
Results
 
MCF-7 cells are widely used as a model for the molecular
analysis of estrogens actions. To identify and purify pro-
teins associated with the estrogen receptor, nuclear extract
was prepared from MCF-7 cells and applied to a phospho-
cellulose column in the presence of 0.1 M KCl. The col-
umn was eluted with three different salt concentrations
(0.3, 0.5, and 0.75 M KCl). Western blot analysis with an
mAb to estrogen receptor of the flowthrough and three
elution fractions is presented in Fig. 1 (
 
left)
 
. This analysis
was performed with the antibody AER317, directed to an
epitope localized in the last 70 aas of the estrogen receptor
molecule. The antibody revealed an intense 67-kD band in
the 0.3 M KCl fraction, indicating that most of the recep-
tor molecules were eluted in it. Fainter bands of the same
molecular weight were visible in the flowthrough and in
the 0.5 M KCl fractions. Similar results were obtained with
other mAbs to estrogen receptor, namely AER314 (epitope
mapping between aa 125 and 165) and 1603 (epitope map-
ping between aa 500 and 595) (data not shown). Immuno-
precipitation of the fractions with the mAb AER317, fol-
lowed by SDS-PAGE analysis, showed that a 104-kD
protein was coimmunoprecipitated with the 67-kD recep-
tor protein only in the flowthrough fraction (Fig. 1,
 
 right
 
).
Another mAb, interacting with the NH
 
2
 
-terminal of the
estrogen receptor molecule (AER314), was unable to im-
munoprecipitate any protein in the flowthrough fraction
(data not shown). This 104-kD band was the most promi-
nent, but a few faint high molecular weight bands and
bands in the 20–40-kD range were also visible. This result
indicated that the estrogen receptor in the flowthrough
fraction was presumably complexed with other protein
moieties and that in this complex the epitope for the
AER314 antibody was masked.
To characterize these proteins, the AER317 immuno-
precipitates of the phosphocellulose column flowthrough
fraction were used to immunize mice and their spleen cells
were used for hybridoma production. Four cloned hybri-
doma cell lines (1011, 1014, 1027, and 1032) were selected,
by Western blot analysis, for the interaction of their anti-
body with the 104-kD protein coimmunoprecipitated by
the antibody to estrogen receptor AER317. The antibody
1032 recognized a 104-kD protein in the nuclear extract by
Western blot analysis (Fig. 2,
 
 left). The 104-kD protein
reacting with the 1032 antibody was most abundantly
present only in the flowthrough fraction of the phospho-
cellulose column and faintly in the 0.3 M KCl fraction (Fig.
2, left). This protein was coimmunoprecipitated from the
flowthrough fraction only by the AER317 antibody and
not by the AER314 (Fig. 2, right), as demonstrated by
Figure 1. Western blot analysis of estrogen receptor in the nu-
clear extract separated by phosphocellulose chromatography and
identification of proteins coimmunoprecipitated with the estro-
gen receptor. Arrows on the left side indicate the migration of
standard proteins of the indicated molecular weight (kD). (Left)
SDS-PAGE followed by Western blot analysis with the mAb to
estrogen receptor AER317 of the flowthrough (lane A), 0.3 M
(lane B), 0.5 M (lane C), or 0.75 M KCl (lane D) fractions of the
phosphocellulose chromatography of MCF-7 cell nuclear extract.
(Right) SDS-PAGE analysis followed by Coomassie blue staining
of the gel of proteins immunoprecipitated with the mAb to estro-
gen receptor AER317 (lanes marked by solid circle) or control
IgG (lanes marked by open circle) of the flowthrough (lanes A),
0.3 M (lanes B), or 0.5 M (lanes C) fractions of the phosphocellu-
lose chromatography of nuclear extract.Abbondanza et al. Interaction of Vault Particles with Estrogen Receptor 1305
Western blot analysis. These results suggested that these
antibodies were directed against the same protein forming
complexes with the estrogen receptor molecule and pre-
venting its recognition by the antibody AER314. Similar
analysis performed with three other selected mAbs (1011,
1014, and 1027) gave comparable results, even though the
antibodies 1014 and 1032 recognized different degradation
fragments of the 104-kD band, thus suggesting that they
were directed to different epitopes (data not shown).
The antibodies 1032 and 1014 recognized a 104-kD band
also in HeLa cell nuclear extract (data not shown) and
therefore, were used to screen a commercial HeLa cell ex-
pression library. Two lambda clones were selected and
their inserted DNA sequenced. Sequence comparison with
nucleic acid sequence databases indicated a 100% homol-
ogy of both fragments with the cDNA sequence coding for
the LRP/human major vault protein (these sequence data
are available from GenBank/EMBL/DDBJ under acces-
sion No. X79882), between bases 686–1251 and 301–1001,
respectively.
The major vault protein is the major component of vault
ribonucleoprotein particles. To investigate whether the es-
trogen receptor interacted with the assembled particle or
with soluble 104-kD protein, vaults were isolated from
MCF-7 cell nuclear extract, according to a published pro-
cedure (Kedersha and Rome, 1986), by centrifugation on a
30–60% sucrose gradient. Western blot analysis of the gra-
dient fractions with the mAb 1032 to the major vault pro-
tein showed an asymmetrical distribution of vaults in the
expected region of the gradient, consistent with a sedimen-
tation coefficient of 150 S. Western blot analysis of the
same fractions with mAb AER317 indicated the presence
of estrogen receptor in the top gradient fractions and in
the peak fractions of anti-104-kD protein reactivity (Fig. 3,
top). Fractions of a similar preparative gradient were incu-
bated with the AER317 antibody and the immunoprecipi-
tated proteins subjected to SDS-PAGE and Western blot
analysis with the 1032 antibody to the major vault protein.
The results (Fig. 3, bottom) indicated that the anti-estro-
gen receptor antibody was able to coprecipitate the 104-kD
protein in the vault peak fractions, thus confirming that es-
trogen receptor was interacting with assembled vaults. In
both experiments, the peak of estrogen receptor immu-
noreactivity corresponded with the left side of the vault
peak.
Since vaults were originally described as cytoplasmic
particles and estrogen receptor is also present in the 20,000 g
supernatant fraction, we performed the immunoprecipita-
tion with the mAb AER317 to estrogen receptor, followed
Figure 2. Western blot analysis of the 104-kD protein in the nu-
clear extract separated by phosphocellulose chromatography and
in the proteins coimmunoprecipitated with the estrogen receptor
in the flowthrough fraction. Arrows on the left side indicate the
migration of standard proteins of the indicated molecular weight
(kD). (Left) SDS-PAGE followed by Western blot analysis with
mAb 1032 to the major vault protein of MCF-7 cells nuclear ex-
tract (lane O) and of the flowthrough (lane A), 0.3 M (lane B),
0.5 M (lane C), or 0.75 M KCl (lane D) fractions of the phospho-
cellulose chromatography of nuclear extract. (Right) SDS-PAGE
followed by Western blot analysis with mAb 1032 to the major
vault protein of proteins immunoprecipitated with the mAbs to
estrogen receptor AER314 (gray circle) and AER317 (solid cir-
cle) or control IgG (open circle) of the flowthrough fraction of
the phosphocellulose chromatography of nuclear extract.
Figure 3. Western blot analysis and immunopre-
cipitation of vaults sedimented through a sucrose
gradient. Arrows on the left side indicate the mo-
lecular weight (kD) of bands calculated from mi-
gration of standard proteins; on the top of the
frames is reported the sedimentation of 80 S ri-
bosomal subunit (external marker). (Top) SDS-
PAGE followed by Western blot analysis with
mAbs 1032 to the major vault protein or
AER317 to estrogen receptor, as indicated, of
fractions of a 5-ml sucrose gradient separation of
the flowthrough of phosphocellulose chromatog-
raphy of nuclear extract. (Bottom) SDS-PAGE
followed by Western blot analysis with mAb
1032 to the major vault protein of proteins im-
munoprecipitated with the mAb to estrogen re-
ceptor AER317 (lower frame) from fractions
(upper frame) of a 40-ml sucrose gradient separa-
tion of the flowthrough of phosphocellulose
chromatography of nuclear extract.The Journal of Cell Biology, Volume 141, 1998 1306
by Western blot analysis with the 1032 antibody to the ma-
jor vault protein. The result, presented in Fig. 4, showed
that the 104-kD major vault protein was coimmunoprecip-
itated in the 20,000 g supernatant as well as in the nuclear
extract from cells grown in undeprived medium. Determi-
nation of lactate dehydrogenase activity indicated that the
cytoplasmic contamination of nuclear extract was z1%
(data not shown). To confirm that estrogen receptor was
associated with vault particles also in the 20,000 g superna-
tant fraction, specific vRNA probing was performed in the
immunoprecipitates. The RNA extracted from immuno-
precipitates was electrophoresed and analyzed by Northern
blot using a human vRNA probe. This probe was obtained
by reverse transcription followed by PCR amplification of
total RNA from MCF-7 cell line, using degenerated con-
sensus primers designed from published rat and bullfrog
vRNA sequences (Kickhoefer et al., 1993). Sequence anal-
ysis of several cloned PCR products showed two frag-
ments species of 82 and 92 bp, respectively. These two
fragments shared z86% identity with each other and
z74–81% identity with rat and bullfrog vRNAs. Agarose
electrophoresis followed by Northern blot analysis of the
RNA coimmunoprecipitated from either cytosol or nu-
clear extract showed a band of z90 nucleotides (nt). This
finding therefore definitely confirmed that estrogen recep-
tor was associated to the assembled vaults.
Reconstitution experiments were attempted in order to
identify the region of the estrogen receptor molecule in-
volved with the interaction. Fusion protein of estrogen re-
ceptor fragments and GST were prepared by expression of
deletion mutants generated in the pGEX-2TK vector sys-
tem. Using an affinity chromatography strategy, the re-
combinant proteins adsorbed to glutathione-coupled Seph-
arose (Kaelin et al., 1991) were incubated with aliquots of
nuclear extract and the amount of 104-kD vault protein
adsorbed was assayed by SDS-PAGE followed by West-
ern blot with antibody 1032. The results are summarized in
Fig. 5 and showed that only the fragments containing the
sequence between aa 241 and 280 (Fig. 5, b–e and h) were
able to retain the 104-kD vault protein. The synthetic re-
ceptor fragment interacting with the major vault protein
and containing the estradiol binding site (aa 241–595) was
incubated with the nuclear extract also in the presence of a
physiological concentration of estradiol. The presence of
estradiol did not affect the extent of the interaction (Fig. 5,
lane d).
Vault concentration in the nuclear extract was affected
by estrogen treatment of MCF-7 cells. The presence of es-
tradiol in the tissue culture medium before cell harvesting
produced a biphasic effect. An initial, transient reduction
of vault concentration was followed by a moderate and
steady increase, peaking at 6–9 h. The pure anti-estrogen
ICI182,780 was also responsible for a biphasic effect, but
never able to produce an increase of vault concentration at
6–9 h above baseline level. Densitometric analysis of the
104-kD band revealed in the Western blots by the anti-
body 1032 is presented in Fig. 6 a. Immunoprecipitation of
Figure 4. Western blot analysis of the 104-kD protein and North-
ern blot analysis of vRNA coimmunoprecipitated with estrogen
receptor in the 20,000 g supernatant of cell extract. (Top) SDS-
PAGE followed by Western blot analysis with mAb 1032 to the
major vault protein of 20,000 g supernatant (lane a), or nuclear
extract (lane b), or of protein immunoprecipitated from 20,000 g
supernatant (lanes c and d), or nuclear extract (lane e) with the
mAb to estrogen receptor AER317 (lanes d and e), or control
IgG (lane c). The arrow on the left side indicates the molecular
weight (kD) of the band calculated from migration of standard
proteins. (Bottom) Northern blot analysis with a human vRNA
probe (see Materials and Methods) of RNA extracted from ali-
quots of samples indicated in the top panel with the correspond-
ing letters. Arrows on the left side indicate the migration of stan-
dard RNA (nt).
Figure 5. Mapping the estrogen receptor region interacting with
the 104-kD protein. SDS-PAGE followed by Western blot analy-
sis with mAb 1032 to the major vault protein of proteins immu-
nopurified on columns containing Sepharose coupled to the indi-
cated fusion proteins. Nuclear extracts were incubated in the
absence (lanes a–c and e–k) or in the presence of 10 nM estradiol
(lane  d). The arrow on the left side indicates the molecular
weight (kD) of the band calculated from migration of standard
proteins. The domain organization of estrogen receptor is re-
ported in scale. On the top, a double-line segment reports the
minimum determined fragment of the estrogen receptor se-
quence necessary for interaction with the major vault protein.Abbondanza et al. Interaction of Vault Particles with Estrogen Receptor 1307
these nuclear extracts with the antibody to estrogen recep-
tor 1603 resulted in a twofold increase of 104-kD vault
protein coimmunoprecipitated with estrogen receptor at
6–9 h. Densitometric profile of the 104-kD band, revealed
by the antibody 1032 in the Western blots analysis of the
immunoprecipitates, is presented in the Fig. 6 b. Treat-
ment with the pure anti-estrogen ICI182,780, on the con-
trary, produced a reduction of the coimmunoprecipitated
104-kD band.
The finding presented in Fig. 6 suggested that the associ-
ation of estrogen receptor with vaults could be hormone
dependent. To better document the estradiol effect on the
vault-estrogen receptor interaction, we attempted to re-
produce it in vitro, using the postnuclear supernatant of
hormone-deprived cells, because it contains both vaults
and native, uncomplexed receptor (Fig. 7 top, lane a). The
postnuclear supernatant was treated with hormones, incu-
bated for 30 min at 308C, to allow for receptor activation,
and then centrifuged to obtain the vault-enriched fraction.
These fractions were analyzed by SDS-PAGE, followed
by Western blot with the antibodies 1032 to the major
vault protein and 1603 to estrogen receptor (Fig. 7 top).
The presence of a physiological concentration of estradiol
increased the amount of estrogen receptor partitioned
with the vault-enriched fraction, whereas the anti-estrogen
ICI182,780 was ineffective. Sodium molybdate prevented
the association of estrogen receptor with the vault-
enriched fraction. Aliquots of the vault-enriched fractions
were incubated with the antibody 1603 to estrogen recep-
tor and the immunoprecipitates analyzed by Western blot
with the antibody 1032 to the major vault protein (Fig. 7
bottom). The coimmunoprecipitation of the 104-kD vault
protein confirmed that estrogen receptor was indeed asso-
ciated with vault particles. However, the intensity of the
104-kD band from the estrogen-treated aliquot did not
show an increase consistent with the increase of estrogen
receptor cosedimenting with vaults. This could be due to
the use of a limiting concentration of the antibody 1603
used for immunoprecipitation. It could be otherwise ex-
plained with the fact that the estradiol effect represents
the interaction of more than one receptor molecule with
each vault. The results presented in Fig. 7 indicated that
also in vitro, in the absence of nuclei, estrogen receptor
was able to complex with vaults in an estrogen-dependent
manner, whereas the anti-estrogen was ineffective. Fur-
thermore, the absence of estrogen receptor in the vault-
enriched fraction in the presence of sodium molybdate in-
dicated that the so-called “native” form of receptor was
unable to complex with vaults. Sodium molybdate, in fact,
prevents the quaternary structure changes of estrogen re-
ceptor induced by temperature and interaction with the
ligand, preserving the complex containing the hsp90.
To investigate whether the association with vaults was
shared by other proteins involved in the nuclear receptor
signaling pathway, we selected three other nuclear recep-
tors and two proteins involved in nuclear receptor tran-
scriptional activation. The nuclear extract of cells grown
in complete medium was incubated with antibodies to
progesterone and glucocorticoid receptors, to Nurr77, an
orphan receptor, to the transcription factor TFIIB or to
SRC-1, a coactivator that is required for full transcrip-
tional activity of the steroid receptor superfamily (Oñate
Figure 6. Time course estrogen effect on the amount of the 104-kD
protein present in the nuclear extract and coimmunoprecipitated
with the estrogen receptor. SDS-PAGE followed by Western blot
analysis with mAb 1032 to the major vault protein of nuclear
extracts (a) or of proteins immunoprecipitated from nuclear ex-
tracts with the mAb 1603 to estrogen receptor (b) of cells incu-
bated in the presence of 10 nM estradiol or 100 nM ICI182,780
for the indicated time. The arrows on the left side indicate the
molecular weight (kD) of the band calculated from migration of
standard proteins; the plots on the bottom are the densitometric
analysis of the blots (d, estradiol; n, ICI182,780).
Figure 7. Western blot anal-
ysis of the estrogen receptor
associated with the vault-
enriched fraction after cell-
free activation of the postnu-
clear supernatant by hormone
and temperature. The arrows
on the left side indicate the
molecular weight (kD) of bands calculated from migration of
standard proteins. (Top) SDS-PAGE followed by Western blot
analysis with mAb 1032 to the major vault protein or 1603 to es-
trogen receptor, as indicated, of postnuclear supernatant (lane a),
vault-enriched fractions from aliquots of postnuclear supernatant
incubated for 30 min at 308C (lanes b–e), in the presence of 10 nM
estradiol (lane c), 100 nM ICI182,780 (lane d), or 5 mM sodium
molybdate (lane e). (Bottom) SDS-PAGE followed by Western
blot analysis with mAb 1032 to the major vault protein of pro-
teins immunoprecipitated with control antibodies (lane a) or with
the mAb 1603 to estrogen receptor (lanes b–d) from the same
samples of lanes b–d of the top panel.The Journal of Cell Biology, Volume 141, 1998 1308
et al., 1995), and that recently has been demonstrated to
have an intrinsic histone acetyltransferase activity (Spen-
cer et al., 1997). For the last two proteins, association to
estrogen receptor had been previously demonstrated. A
commercial antiserum to estrogen receptor was also
tested. Immunoprecipitated proteins were analyzed by
Western blot with the monoclonal antibody 1032 to the
major vault protein and the result presented in Fig. 8 (top).
The antibody to progesterone receptor was able to coim-
munoprecipitate the 104-kD vault protein, even though to
a lesser extent than both antibodies to estrogen receptor.
The antibodies to glucocorticoid receptor, to Nurr77 and
to TFIIB co-immunoprecipitated a very small amount of
104-kD major vault protein, whereas the antibody to SRC-1
did not. To confirm that progesterone receptor was also
associated with vault particles, the nuclear extract was ap-
plied to a phosphocellulose column and the flowthrough
fraction separated on a sucrose gradient. Western blot
analysis was performed on the gradient fractions with the
antibodies 1032 (to the major vault protein) and C-262 (to
progesterone receptor). The result, presented in Fig. 8
(bottom), indicated that a fraction of the total progester-
one receptor present in the extract cosedimented with the
vault particle peak.
Discussion
The interaction of vaults with the estrogen receptor mole-
cule is as puzzling as their involvement with multi-drug re-
sistance mechanisms. No other protein with a defined bio-
logical function has been described to be associated with
vaults. It is hard, therefore, to predict the biological mean-
ing of the interaction described here within the estradiol
mechanism of action. The molecular mechanism of steroid
hormone action relays on precise DNA and protein con-
tacts with the receptor molecule (Kumar et al., 1986;
Mader et al., 1989; Medici et al., 1991). Specific DNA
binding of the receptor to the hormone responsive ele-
ments is a necessary but not sufficient step for activating
transcription (Mayer et al., 1989). Ligand-activated recep-
tors communicate with the transcriptional apparatus by
contact with bridging molecules or directly with basal tran-
scription factors (Ing et al., 1992; Cavaillès et al., 1994,
1995; Halachmi et al., 1994; Jacq et al., 1994; Le Douarin
et al., 1995; Oñate et al., 1995; Voegel et al., 1996; vom
Baur et al., 1996). It is conceivable that other proteins
might interact with the receptor molecule for the correct
implementation of other tasks related to signal transduc-
tion, such as receptor recycling and/or processing, and in-
tracellular homing. Given the transient nature of these in-
teractions, it was not surprising that only a limited amount
of the estrogen receptor molecules present in the nuclear
extract was associated with the major vault protein.
Although the selective immunoprecipitation of the 104-kD
protein with the AER317 and not with the AER314 anti-
body suggested that the A/B domain of estrogen receptor
was involved in the interaction, a different evidence came
from reconstitution experiments with the recombinant re-
ceptor fragments. The result presented in Fig. 5 indicated
that the region necessary for the interaction was in the
COOH-terminal extremity of the DNA-binding domain
and in the hinge region (domains C and D), between aa
241 and 340. A fragment containing only part of this se-
quence showed partial interaction, suggesting the exist-
ence of more than one contact involved. These results are
consistent with the hypothesis that the interaction with the
vault protein mediates the process of nuclear transport of
the receptor molecule. In fact, three proto-nuclear local-
ization signals, cooperating for the estradiol-independent
nuclear localization of the receptor, have been mapped to
the same region (Picard et al., 1990, Ylikomi et al., 1992).
This evidence may support the hypothesis that vaults are
part of the central plug of the nucleopore (Chugani et al.,
1993).
A functional relevance for vaults–estrogen receptor in-
teraction was strongly supported by the evidence that a
physiological concentration of estradiol increased the
number of estrogen receptor molecules interacting with
vaults both in cultured cells and in in vitro preparations.
Even though this effect was not dramatic, it was not ob-
tained with the ICI182,780. This molecule is a potent and
specific inhibitor of estrogen action and in both animal
models and human studies is considered a pure antagonist
(Wakeling et al., 1991). The in vitro reconstitution experi-
ments, however, did not show hormone dependency of the
interaction between the estrogen receptor fragments and
the vault protein. This discrepancy may be explained with
the presence of a fourth hormone-regulated nuclear local-
ization signal in the hormone-binding domain of the re-
ceptor or by the intervention of other intracellular ele-
ments to the assembly of the complex. In the same region
of the estrogen receptor, where we mapped the interaction
Figure 8. Western blot analysis of the 104-kD
protein and coimmunoprecipitated by antibodies
to other nuclear proteins. The arrows on the left
side indicate the molecular weight (kD) of the
bands calculated from migration of standard pro-
teins. The arrows on the left side indicate the mo-
lecular weight (kD) of the bands calculated from
migration of standard proteins. (Top) SDS-
PAGE followed by Western blot analysis with
mAb 1032 to the major vault protein of nuclear
extract (lane j) or of proteins immunoprecipi-
tated from the nuclear extract with antibodies to
progesterone receptor (lane a), to glucocorticoid receptor (lane b), to Nurr77 (lane c), to estrogen receptor (lanes d and e, commercial
polyclonal and AER317, respectively), to TFIIB (lane f), to SRC-1 (lane g), or with mouse (lane h) and rabbit control antibodies (lane
i). (Bottom) SDS-PAGE followed by Western blot analysis with mAb 1032 to the major vault protein or C-262 to progesterone recep-
tor, as indicated, of fractions of a 5-ml sucrose gradient separation of the flowthrough of phosphocellulose chromatography of nuclear extract.Abbondanza et al. Interaction of Vault Particles with Estrogen Receptor 1309
with major vault protein, is localized a sequence necessary
for the formation of the 8 S receptor form (Chambraud et
al., 1990). This “native” form, found in the cytosol of tar-
get cells and unable to bind DNA, is formed by estradiol-
binding subunits noncovalently associated with hsp90 (Re-
deuihl et al., 1987). Ligand binding induces the release of
hsp90 from the receptor and its transformation to a DNA-
binding form. Although the interaction of hsp90 with the
receptor involves several receptor regions, the sequence
between aa 251 and 271 is critical for the 8 S formation
(Chambraud et al., 1990). Sodium molybdate is able to
prevent the ligand- and temperature-induced dissociation
of the hsp90 from the hormone-binding subunit, and
therefore preserves the 8 S form. In our experiments, addi-
tion of sodium molybdate prevented the estrogen-induced
interaction of receptor with vaults in the postnuclear su-
pernatant from unstimulated cell. This finding suggested
that interaction of vaults and hsp90 with estrogen receptor
molecule is mutually exclusive. Hsp90 might sterically
hinder the interaction of the receptor with vaults and the
estrogen effect might be mediated by the induction of
hsp90 dissociation. For the glucocorticoid receptor, stabili-
zation of the complex with hsp90 by sodium molybdate in
live cells restricted hormone-dependent nuclear import of
receptor (Yang and De Franco, 1996).
A deeper insight into the nature of vault function will
certainly explain the function of this interaction in the
mechanism of action of estrogenic hormones. Nothing is
known about varieties in vault composition. The asymmet-
rical peak profile of reactivity of sucrose gradient fractions
with the 1032 antibody to the major vault protein sug-
gested that the vault population is not homogeneous and
that the estrogen receptor interacted only with a sub-pop-
ulation of vaults particles. In this respect, it would be inter-
esting to investigate a possible role of vRNA or other pro-
tein moieties in this differential interaction. The RNA
coimmunoprecipitated with the major vault protein by the
antibody to estrogen receptor contained the human
vRNA. The sequence of the fragments cloned from the to-
tal MCF-7 cell RNA and used for probing the Northern
blot matched the sequences identified as human vRNA
genes (Kickhoefer et al., 1998). In particular, the 92-nt
fragment had a 95% similarity with HGV1 and the 82-nt
fragment had a 94% similarity with HGV2. The differ-
ences were limited to the regions covered by degenerated
primers. Our electrophoresis separation was unable to
separate the two bands and, therefore we were unable to
identify which vRNA species was present in the immuno-
precipitates. A regulatory rather than structural role for
vRNA has been postulated, because the presence of
vRNA is not required to maintain the structural integrity
of vaults and it has a very distinct tissue-specific expres-
sion pattern (Kickhoefer et al., 1993). In addition, compar-
ison of computer-generated secondary structures showed
a similarity with other small RNAs (VAI and VAII of ade-
novirus, Epstein-Barr–encoded RNAs, and ribosomal 5 S)
endowed with a regulatory function (Kickhoefer et al.,
1993). Coherent to this hypothesis was the finding that
vRNA was not necessary for the vaults–estrogen receptor
interaction. RNase treatment of nuclear extract did not af-
fect coimmunopurification of vault particles with estrogen
receptor (data not shown).
We have no specific data about the stoichiometry of the
vault-receptor interaction. The intensity of the major vault
protein bands coimmunoprecipitated with estrogen recep-
tor suggested that estradiol treatment may induce an in-
crease in both the number of vaults involved and receptor
molecules interacting with each particle.
Although vaults were originally identified in the postmi-
crosomal supernatant of cell extracts, it has also been re-
ported that they were present in isolated nuclei and that
they can be extracted with 1% Triton X-100 or 150 mM
NaCl washes of nuclei (Chugani et al., 1993). In our exper-
iments, vaults were originally identified in the nuclear ex-
tract from cultured MCF-7 cells. The nuclear extract was
prepared according to a protocol optimized for the recov-
ery of cell-free transcription activity by RNA polymerase
rather than for integrity of the nuclear preparation. The
amount of 104-kD major vault protein present in our nu-
clear extract was z1/10th of that present in the cytosol
fraction. Coimmunoprecipitation of vaults with the estro-
gen receptor also in the postnuclear supernatant or in the
vault-enriched fraction indicated that the interaction of es-
trogen receptor was not selective for vaults present in the
nuclear extract. However, a precise intracellular localiza-
tion of vaults interacting with estrogen receptor would re-
quire a double-labeling immunocytochemistry study and it
is out of the aim of this report.
Taken together, these evidences allowed us to speculate
that the interaction between estrogen receptor and vaults
is probably related to the intracellular transport. The exist-
ence of an energy-dependent nucleo–cytoplasmic shuttle
mechanism has been demonstrated for progesterone and
estrogen receptors (Guiochon-Mantel et al., 1991). An ac-
tive, regulated transport of estrogen receptor between nu-
cleus and cytoplasm might establish a further control step
in the mechanism of hormone action. Differential parti-
tioning of receptor molecules between intracellular com-
partments (nucleus/cytoplasm) might modulate the sen-
sitivity of a target cell to hormone, adjusting the intranuclear
receptor concentration. It is reasonable to assume that
such control mechanism could be modified by estradiol it-
self—thus participating to the receptor downregulation ef-
fect—or by interfering signal transduction pathways or by
other integrated intracellular functions. The evidence that
progesterone receptor cosedimented with vaults and that
antibodies to glucocorticoid receptor and to Nurr77 were
able to immunoprecipitate the 104-kD major vault protein
suggested that interaction with this particle is a property
common to more than one member of the nuclear recep-
tor superfamily. If this is the case, vaults might be involved
in a general mechanism of nucleo–cytoplasmic shuttle for
modulation of signal transduction of steroid hormones.
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